Abstract
Mammary tumours are oestrogen dependent in female Sprague-Dawley rats and in a significant proportion of women, so pharmacological treatment to inhibit oestrogen production is a valuable therapeutic measure to prevent or slow the progression of disease. Here we show that a non-steroidal aromatase inhibitor, which competitively inhibits the conversion of androstenedione to oestrone, prevents the development of both benign and malignant spontaneous mammary neoplasms in female Sprague-Dawley ats. It also slows the spontaneous development of pituitary pars distalis adenomas in female rats, and reduces the incidence of spontaneous hepatocellular tumours in male and female rats.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gunson, D., Steele, R. & Chau, R. Prevention of spontaneous tumours in female rats by fadrozole hydrochloride, an aromatase inhibitor. Br J Cancer 72, 72–75 (1995). https://doi.org/10.1038/bjc.1995.279
Issue Date:
DOI: https://doi.org/10.1038/bjc.1995.279
This article is cited by
-
The Emerging Roles of Steroid Hormone Receptors in Ductal Carcinoma in Situ (DCIS) of the Breast
Journal of Mammary Gland Biology and Neoplasia (2018)
-
Role of estrogen in hepatocellular carcinoma: is inflammation the key?
Journal of Translational Medicine (2014)
-
Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk
British Journal of Cancer (1999)